GO:0050925 negative regulation of negative chemotaxis: Signaling Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050925 (negative regulation of negative chemotaxis) describes any process that stops, prevents, or reduces the directed movement of a motile cell or organism away from a chemical gradient.
• It is a biological_process term that acts as a brake on repulsive (negative) chemotaxis, thereby helping cells retain or redirect position within a chemical gradient.
• Key molecular brakes include the lipid phosphatase activity of PTEN on CXCR4-mediated chemotaxis, the adaptor protein p66Shc on B-cell chemokine receptor signaling, and receptor-type regulation exemplified by PDGF receptor-beta.
• Dysregulation of this process is linked to cancer metastasis, chronic inflammation, and impaired immune cell positioning.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are the primary tools for causally testing candidate regulators of this process.
• The term is distinct from positive chemotaxis and from general negative regulation of cell migration; it specifically targets movement toward lower chemical concentration.
Description
Negative regulation of negative chemotaxis (GO:0050925) is a biological_process term that captures the cellular mechanisms which suppress or dampen repulsive chemotaxis, the directed movement of a motile cell or organism toward a lower concentration of a chemical gradient. In contrast to attractive (positive) chemotaxis, negative chemotaxis drives cells away from a repellent or from a high-concentration source; the negative regulation of this behavior therefore acts as a positioning brake that keeps cells from over-responding to repulsive cues. This regulatory layer is essential for immune cell retention, tissue patterning, and preventing excessive dispersal of cells during development and inflammation. Mechanistically, negative regulation of negative chemotaxis is achieved through intracellular signaling brakes that intersect with chemokine receptor pathways. For example, the lipid phosphatase activity of PTEN negatively regulates CXCR4-mediated chemotaxis, thereby reducing directional migration of cells toward a CXCR4 ligand gradient. Similarly, the adaptor protein p66Shc negatively regulates chemokine receptor signaling and B-cell chemotaxis, providing a molecular brake on repulsive movement. Receptor tyrosine kinases such as PDGF receptor-beta also modulate chemotactic responses, illustrating that the regulation of negative chemotaxis is integrated with growth factor signaling. For researchers, GO:0050925 matters because it defines a specific, testable node in cell migration control. Loss-of-function or gain-of-function perturbations of the genes that mediate this process can shift the balance between retention and repulsion, with consequences for cancer invasion, immune surveillance, and inflammatory disease. Understanding this term also helps annotate high-throughput datasets and CRISPR screens that measure directional migration phenotypes.
negative regulation of negative chemotaxis At A Glance
| GO ID | GO:0050925 |
|---|---|
| GO term | negative regulation of negative chemotaxis |
| Ontology | biological_process |
| Synonym | down regulation of negative chemotaxis; down-regulation of negative chemotaxis; downregulation of negative chemotaxis; inhibition of negative chemotaxis |
| Major function | Suppresses or reduces directed movement of a motile cell or organism toward a lower concentration of a chemical gradient |
| Regulated process | Negative chemotaxis (GO:0050919) |
| Regulation direction | Negative regulation (down-regulation / inhibition) |
| Example regulators | PTEN, p66Shc, PDGF receptor-beta, CXCR4 pathway components |
| Disease relevance | Cancer metastasis, chronic inflammation, immune cell positioning |
What Is GO:0050925?
In plain terms, GO:0050925 describes any cellular process that reduces, stops, or prevents a cell or organism from moving away from a chemical along a concentration gradient. The official QuickGO definition states: Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a motile cell or organism towards a lower concentration in a concentration gradient of a specific chemical. It is a biological_process term whose synonyms include down regulation of negative chemotaxis, down-regulation of negative chemotaxis, downregulation of negative chemotaxis, and inhibition of negative chemotaxis.
Why Is negative regulation of negative chemotaxis Important in Cell Biology?
GO:0050925 is important because it provides a precise vocabulary for the braking mechanisms that control repulsive cell migration. Cells rarely respond to a single gradient in isolation; they integrate attractive and repulsive cues, and the negative regulation of negative chemotaxis determines whether a cell remains in a tissue or escapes along a repellent gradient. This regulatory node is directly relevant to cancer biology, where chemokine receptor signaling and PTEN status influence metastatic dissemination, and to immunology, where p66Shc and purinergic signals shape B-cell and airway inflammatory responses. Because the term is defined operationally, it can be assayed with standard chemotaxis platforms and perturbed with CRISPR models, making it a tractable target for mechanistic and translational research.
• Defines a specific regulatory brake on repulsive (negative) chemotaxis, distinct from general migration control.
• PTEN lipid phosphatase activity negatively regulates CXCR4-mediated chemotaxis, linking the term to tumor suppressor function.
• p66Shc negatively regulates chemokine receptor signaling and B-cell chemotaxis, connecting the term to immune cell trafficking.
• PDGF receptor-beta regulates chemotaxis, showing integration with receptor tyrosine kinase signaling.
• Relevant to cancer metastasis because CXCR4-mediated chemotaxis and chemoinvasion are modulated by this regulatory layer.
• Relevant to inflammation because purinergic regulation of airway inflammation involves chemotactic control.
• Provides annotation logic for CRISPR screens and transcriptomic datasets measuring directional migration.
• Supports comparative analysis of M1 vs M2 macrophage gene signatures, where chemotaxis-related programs differ.
• Helps interpret bacterial chemotaxis regulation by environmental nitrogen source as an evolutionary contrast.
• Enables hypothesis-driven testing of whether a candidate gene causally changes repulsive migration.
What Happens During negative regulation of negative chemotaxis?
Sensing the repulsive gradient and initiating negative chemotaxis
In simple terms: First, the cell detects a chemical that it dislikes and starts moving away from it.
Negative chemotaxis begins when a motile cell or organism detects a chemical gradient and orients its movement toward lower concentration. This directional sensing requires a chemotactic compass that establishes cell polarity and coordinates the cytoskeleton. In eukaryotic cells, chemokine receptors such as CXCR4 can mediate directed migration, and the strength of this response is subject to negative regulation. The initial sensing step is therefore the substrate upon which GO:0050925 acts: without a repulsive gradient response, there is nothing to negatively regulate.
Recruitment of intracellular brakes that suppress the repulsive response
In simple terms: The cell then switches on internal braking proteins that weaken the urge to move away.
Once negative chemotaxis is engaged, specific intracellular regulators can suppress it. The lipid phosphatase activity of PTEN negatively regulates CXCR4-mediated chemotaxis, reducing the extent of directed movement. The adaptor protein p66Shc negatively regulates chemokine receptor signaling and B-cell chemotaxis, providing a second braking mechanism. These examples show that GO:0050925 is executed by defined signaling molecules rather than by a nonspecific loss of motility.
Receptor-level modulation of chemotactic signaling
In simple terms: Brakes can also act at the receptor itself, changing how strongly the cell hears the repulsive signal.
Receptor tyrosine kinases and chemokine receptors are convergence points for negative regulation. PDGF receptor-beta regulates chemotaxis, demonstrating that growth factor receptor signaling can modulate directional movement. In breast cancer cells, CXCR4-mediated chemotaxis and chemoinvasion are regulated processes that can be dampened by upstream signals. This subsection emphasizes that GO:0050925 can be implemented at the receptor-proximal level, altering signal transduction before the cytoskeletal machinery commits to movement.
Integration with inflammatory and purinergic cues
In simple terms: Inflammation signals can tune the brakes on repulsive movement.
Purinergic regulation of airway inflammation illustrates how extracellular nucleotides and their receptors shape inflammatory cell behavior, including chemotactic responses. Macrophage polarization states also carry distinct chemotaxis-related gene signatures, with M1 and M2 macrophages differing in their migratory programs. Together, these findings indicate that GO:0050925 operates within a broader inflammatory network, where the negative regulation of negative chemotaxis helps determine whether immune cells accumulate or disperse.
Outcome: retention, redirection, or reduced dispersal
In simple terms: The end result is that the cell stays put more, or moves away less, than it otherwise would.
The functional outcome of negative regulation of negative chemotaxis is a reduction in the frequency, rate, or extent of movement toward lower chemical concentration. This can manifest as cell retention within a tissue, redirection toward other cues, or reduced dispersal from a niche. Because the term is defined by its effect on negative chemotaxis, assays must measure directional movement rather than random motility. Comparative studies in bacteria show that chemotaxis regulation is sensitive to environmental conditions such as nitrogen source, underscoring that context determines the net outcome.
Key Genes Involved in GO:0050925 negative regulation of negative chemotaxis
The following genes and proteins have been experimentally implicated in the regulation of chemotaxis and are directly relevant to studying GO:0050925.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTEN | Lipid phosphatase that negatively regulates CXCR4-mediated chemotaxis | Tumor suppressor; loss alters chemotactic braking |
| CXCR4 | Chemokine receptor mediating chemotaxis and chemoinvasion | Central receptor in cancer and immune migration |
| SHC1 (p66Shc) | Adaptor protein negatively regulating chemokine receptor signaling and B-cell chemotaxis | Immune cell trafficking brake |
| PDGFRB | Receptor tyrosine kinase regulating chemotaxis | Growth factor control of directional movement |
| P2RY receptors | Purinergic receptors modulating inflammatory chemotaxis | Airway inflammation and nucleotide signaling |
| CCR7 | Chemokine receptor in B-cell and dendritic cell migration | Context for p66Shc-mediated regulation |
| CXCL12 | Ligand for CXCR4 | Gradient source in chemotaxis assays |
| PTK2 (FAK) | Focal adhesion kinase in migratory signaling | Downstream cytoskeletal integration |
| RAC1 | Rho GTPase controlling actin polarity | Chemotactic compass component |
| CDC42 | Rho GTPase regulating cell polarity | Directional sensing machinery |
| PIK3CA | PI3K catalytic subunit in chemotactic signaling | Lipid signaling node opposed by PTEN |
| AKT1 | Serine/threonine kinase downstream of PI3K | Survival and migration signaling |
| MAPK1 | Mitogen-activated protein kinase in chemotaxis | Receptor-proximal signaling |
| IL4 | Cytokine shaping M2 macrophage polarization | Chemotaxis gene signature context |
| IFNG | Cytokine shaping M1 macrophage polarization | Chemotaxis gene signature context |
| P2RX7 | Purinergic receptor in inflammation | Airway inflammatory chemotaxis |
| CheY (bacterial) | Response regulator in bacterial chemotaxis | Evolutionary contrast for chemotaxis regulation |
How Is negative regulation of negative chemotaxis Regulated?
The process described by GO:0050925 is itself regulated at multiple levels. PTEN lipid phosphatase activity provides a direct enzymatic brake on CXCR4-mediated chemotaxis, meaning that loss of PTEN removes a negative regulator of a negative chemotactic response. p66Shc similarly acts as a negative regulator of chemokine receptor signaling in B cells. Receptor tyrosine kinase signaling through PDGF receptor-beta can modulate chemotactic output, indicating that growth factor pathways intersect with this regulatory node. Inflammatory and purinergic cues further tune the system, as shown in airway inflammation models. Finally, macrophage polarization states are associated with distinct chemotaxis-related gene signatures, suggesting that cellular activation status sets the baseline for negative regulation of negative chemotaxis.
negative regulation of negative chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTEN | Cancer metastasis; chemotaxis braking | PTEN knockout cancer cell line with CXCR4 chemotaxis assay |
| CXCR4 | Breast cancer chemoinvasion | CXCR4 overexpression and knockdown in breast cancer cells |
| SHC1 (p66Shc) | B-cell trafficking and inflammation | p66Shc knockout B cells in chemotaxis assays |
| PDGFRB | Growth factor-driven migration | PDGFRB point-mutation knock-in in fibroblasts |
| P2RY / P2RX7 | Airway inflammation | Purinergic receptor knockout in inflammatory models |
Cancer metastasis and chemoinvasion
CXCR4-mediated chemotaxis and chemoinvasion are central to cancer cell dissemination, and their regulation by PTEN lipid phosphatase activity directly affects metastatic potential. When negative regulation of negative chemotaxis is weakened, cancer cells may respond more strongly to chemokine gradients and invade more aggressively. This makes GO:0050925 a conceptual framework for understanding how tumor suppressors restrain migratory behavior.
Chronic inflammation and immune cell positioning
p66Shc negatively regulates chemokine receptor signaling and B-cell chemotaxis, linking GO:0050925 to immune cell trafficking and inflammatory disease. Purinergic regulation of airway inflammation further shows that chemotactic control is embedded in inflammatory networks. Macrophage polarization states with distinct chemotaxis gene signatures suggest that inflammatory activation reshapes this regulatory layer.
Infectious disease and microbial chemotaxis
Bacterial chemotaxis is regulated by environmental conditions such as the nitrogen source, as shown in Pseudomonas aeruginosa. Although mechanistically distinct from eukaryotic negative regulation of negative chemotaxis, this example highlights the evolutionary importance of chemotaxis control and provides a comparative framework for understanding GO:0050925.
From negative regulation of negative chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PTEN enhance CXCR4-mediated chemotaxis? | PTEN knockout cell line with CXCL12 gradient assay |
| Does p66Shc deletion alter B-cell chemotaxis? | p66Shc knockout primary B cells |
| Does a point mutation in PDGFRB change chemotactic regulation? | PDGFRB point-mutation knock-in fibroblasts |
| Can tagged CXCR4 be used to track receptor trafficking during chemotaxis? | Tagged knock-in CXCR4 cell line |
| Does overexpression of a candidate brake reduce negative chemotaxis? | Overexpression cell model with chemotaxis readout |
| Which genes regulate chemotaxis in macrophages? | CRISPR library screening in polarized macrophages |
How to Study the negative regulation of negative chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell chemotaxis assay | Directional cell movement across a gradient | Testing negative chemotaxis regulation |
| Microfluidic gradient assay | Real-time directional migration | Quantifying repulsive responses |
| CRISPR knockout | Loss-of-function effect on chemotaxis | Testing candidate brakes such as PTEN |
| CRISPR point mutation | Specific residue or domain function | Dissecting PDGFRB signaling |
| CRISPR knock-in (tagged) | Protein localization and trafficking | Tracking CXCR4 during chemotaxis |
| Overexpression | Gain-of-function effect on migration | Testing candidate negative regulators |
| RNA-seq / gene signature | Transcriptomic chemotaxis programs | Macrophage polarization analysis |
| Phospho-signaling assays | Receptor and kinase activation | Chemokine receptor signaling |
Chemotaxis assays (Transwell and microfluidic gradients)
Direct measurement of negative chemotaxis and its regulation requires controlled chemical gradients. Transwell and microfluidic platforms allow quantification of directional movement toward lower concentration, and are the standard readout for GO:0050925-related phenotypes. These assays can be combined with receptor inhibitors or gene perturbations to test whether a candidate gene acts as a brake on negative chemotaxis.
CRISPR perturbation followed by migration phenotyping
CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of candidate regulators. For example, PTEN knockout can be used to test whether loss of lipid phosphatase activity enhances CXCR4-mediated chemotaxis, while p66Shc knockout tests B-cell chemokine receptor regulation. These perturbations are typically paired with chemotaxis assays and signaling readouts.
Transcriptomic and gene signature analysis
RNA-seq and gene signature analysis can identify chemotaxis-related programs across cell states. Macrophage polarization studies have defined distinct M1 and M2 gene signatures that include chemotaxis-related genes, providing a transcriptomic context for GO:0050925. Such analyses help prioritize candidate regulators for functional testing.
Signaling and biochemical assays
Biochemical assays measuring receptor phosphorylation, lipid phosphatase activity, and downstream kinase signaling are used to dissect the molecular brakes on chemotaxis. PTEN lipid phosphatase activity and p66Shc adaptor function have been characterized with such approaches. Receptor tyrosine kinase signaling through PDGF receptor-beta can also be monitored to understand integration with chemotactic pathways.
How CRISPR Can Be Used to Study GO:0050925 negative regulation of negative chemotaxis
Knockout
CRISPR knockout is used to remove a candidate brake and test whether negative chemotaxis increases. PTEN knockout models are a canonical example, where loss of lipid phosphatase activity enhances CXCR4-mediated chemotaxis. p66Shc knockout similarly tests the role of this adaptor in B-cell chemokine receptor regulation. Knockout screens can also be applied to identify new regulators of chemotaxis in polarized macrophages.
Point Mutation
Point-mutation models allow precise dissection of domains required for negative regulation of negative chemotaxis. For example, mutating the lipid phosphatase domain of PTEN can separate its chemotaxis-regulatory function from other activities. Point mutations in receptor tyrosine kinases such as PDGFRB can reveal residues that control chemotactic signaling.
Knock-in
Knock-in of tagged or reporter alleles enables tracking of receptor trafficking and signaling during chemotaxis. A tagged CXCR4 knock-in can be used to follow receptor localization in gradients. Knock-in of disease-associated variants can also test whether specific alleles alter the regulation of negative chemotaxis.
Overexpression
Overexpression models test whether increasing the level of a candidate regulator strengthens the brake on negative chemotaxis. Overexpressing PTEN or p66Shc is expected to reduce chemotactic responses, providing gain-of-function evidence. Overexpression of chemokine receptors such as CXCR4 can conversely increase chemotaxis and chemoinvasion, highlighting the balance between opposing regulators.
How EDITGENE Supports negative regulation of negative chemotaxis Research
Researchers studying negative regulation of negative chemotaxis-related genes often need to determine whether a candidate gene is causally involved in suppressing repulsive migration, or whether it merely correlates with a chemotactic phenotype. Establishing causality requires controlled genetic perturbation, ideally with isogenic models that differ only at the locus of interest. EDITGENE provides the full spectrum of CRISPR cell model engineering needed to move from correlation to mechanism in GO:0050925 research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of negative chemotaxis research.
Frequently Asked Questions About negative regulation of negative chemotaxis
What is GO:0050925 negative regulation of negative chemotaxis?
GO:0050925 is a biological_process term defined as any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a motile cell or organism towards a lower concentration in a concentration gradient of a specific chemical.
What genes are involved in negative regulation of negative chemotaxis?
Experimentally implicated genes include PTEN, which negatively regulates CXCR4-mediated chemotaxis through its lipid phosphatase activity, SHC1 (p66Shc), which negatively regulates chemokine receptor signaling and B-cell chemotaxis, and PDGFRB, which regulates chemotaxis.
How is negative regulation of negative chemotaxis different from negative chemotaxis?
Negative chemotaxis is the directed movement away from a chemical; negative regulation of negative chemotaxis is the process that suppresses or reduces that movement, acting as a brake on the repulsive response.
What diseases are linked to negative regulation of negative chemotaxis?
Cancer metastasis and chemoinvasion through CXCR4 signaling, chronic inflammation and immune cell positioning through p66Shc and purinergic pathways, and macrophage polarization-related migratory programs.
How do you measure negative regulation of negative chemotaxis in the lab?
Transwell and microfluidic gradient assays measure directional movement, and are combined with CRISPR perturbations of candidate regulators such as PTEN or p66Shc.
What is the role of PTEN in negative regulation of negative chemotaxis?
PTEN lipid phosphatase activity negatively regulates CXCR4-mediated chemotaxis, reducing the extent of directed movement toward a chemokine gradient.
What is the role of p66Shc in chemotaxis?
p66Shc negatively regulates chemokine receptor signaling and B-cell chemotaxis, acting as a molecular brake on chemokine-driven migration.
Can CRISPR be used to study negative regulation of negative chemotaxis?
Yes. CRISPR knockout, point-mutation, knock-in, and overexpression models are used to causally test candidate regulators in chemotaxis assays.
What is the chemotactic compass in eukaryotic chemotaxis?
The chemotactic compass is the cell polarity machinery that allows eukaryotic cells to sense and respond directionally to chemical gradients, providing the framework on which negative regulation acts.
Is negative regulation of negative chemotaxis conserved in bacteria?
Bacterial chemotaxis is regulated by environmental conditions such as the nitrogen source in Pseudomonas aeruginosa, showing that chemotaxis control is evolutionarily important, though the molecular players differ from eukaryotic regulators.
Conclusion
GO:0050925 (negative regulation of negative chemotaxis) defines a precise biological_process node that controls how strongly cells move away from chemical gradients. Its experimental basis rests on regulators such as PTEN, p66Shc, and PDGF receptor-beta, which act as brakes on chemokine receptor and growth factor signaling. Because the term is operationally defined, it can be interrogated with standard chemotaxis assays and CRISPR perturbation models. For researchers, GO:0050925 provides a framework for linking molecular brakes to disease-relevant phenotypes in cancer, inflammation, and immune cell positioning. Combining CRISPR cell model engineering with quantitative migration assays offers a direct path from candidate gene to causal mechanism in this regulatory process.
References
- 1. Orecchioni M et al.. 2019. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages.. Front Immunol 10:1084 PMID: 31178859
- 2. Patrussi L et al.. 2014. Negative regulation of chemokine receptor signaling and B-cell chemotaxis by p66Shc.. Cell Death Dis 5(2):e1068 PMID: 24556683
- 3. Fernandis AZ et al.. 2004. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells.. Oncogene 23(1):157-67 PMID: 14712221
- 4. Weiner OD. 2002. Regulation of cell polarity during eukaryotic chemotaxis: the chemotactic compass.. Curr Opin Cell Biol 14(2):196-202 PMID: 11891119
- 5. Koeppen M et al.. 2011. Purinergic regulation of airway inflammation.. Subcell Biochem 55:159-93 PMID: 21560048
- 6. Kundra V et al.. 1994. Regulation of chemotaxis by the platelet-derived growth factor receptor-beta.. Nature 367(6462):474-6 PMID: 8107807
- 7. Gao P et al.. 2005. Negative regulation of CXCR4-mediated chemotaxis by the lipid phosphatase activity of tumor suppressor PTEN.. Blood 106(8):2619-26 PMID: 15994292
- 8. Craven R et al.. 1985. Regulation of Pseudomonas aeruginosa chemotaxis by the nitrogen source.. J Bacteriol 164(2):544-9 PMID: 3932326
